Kaken Pharmaceutical Co., Ltd. (KKPCF)
OTCMKTS
· Delayed Price · Currency is USD
26.78
+26.78 (0.00%)
Jan 31, 2025, 4:00 PM EDT
Kaken Pharmaceutical Revenue
Kaken Pharmaceutical had revenue of 24.62B JPY in the quarter ending December 31, 2024, with 32.97% growth. This brings the company's revenue in the last twelve months to 93.35B, up 29.48% year-over-year. In the fiscal year ending March 31, 2024, Kaken Pharmaceutical had annual revenue of 72.04B, down -1.29%.
Revenue (ttm)
93.35B JPY
Revenue Growth
+29.48%
P/S Ratio
1.80
Revenue / Employee
82.25M JPY
Employees
1,135
Market Cap
1.07B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
| Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
| Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
| Mar 31, 2021 | 74.98B | -14.25B | -15.97% |
| Mar 31, 2020 | 89.23B | -4.93B | -5.24% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Kaken Pharmaceutical News
- 25 days ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 6 months ago - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Benzinga